Double-blind, randomized study evaluating the glycemic and antiinflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β Antibody, in patients with type 2 diabetes

Diabetes Care

Volumn 36, Issue 8, 2013, Pages 2239-2246

  Sloan Lancaster, Joanne ^a   Abu Raddad, Eyas ^a   Polzer, John ^a   Miller, Jeffrey W ^a   Scherer, Joel C ^a   De Gaetano, Andrea ^b   Berg, Jolene K ^c   Landschulz, William H ^a  

^a ELI LILLY AND COMPANY   (United States)

^b CNR   (Italy)

^c Cetero Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; ANTIDIABETIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; C REACTIVE PROTEIN; CHOLESTEROL; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; LOW DENSITY LIPOPROTEIN; LY 2189102; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LY2189102; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADJUVANT THERAPY; ADULT; AGED; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIET THERAPY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FATTY ACID BLOOD LEVEL; FEMALE; FEVER; FLATULENCE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART DISEASE; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LOW DRUG DOSE; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; MUSCLE STRAIN; MUSCULOSKELETAL CHEST PAIN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; VOMITING; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; PLACEBOS;

EID: 84878774925     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1835     Document Type: Article

References (30)

1. Cerasi E, Luft R. Insulin response to glucose infusion in diabetic and non-diabetic monozygotic twin pairs. Genetic control of insulin response? Acta Endocrinol (Copenh) 1967;55:330-345
2. DeFronzo RA. Lilly lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667-687
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-110
4. Hellerström C. The life story of the pancreatic B cell. Diabetologia 1984;26:393-400
5. Donath MY, Halban PA. Decreased betacell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 2004;47:581-589
6. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 2008;31(Suppl. 2):S161-S164
7. Maedler K, Sergeev P, Ris F, et al. Glucoseinduced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002;110: 851-860
8. Maedler K, Spinas GA, Lehmann R, et al. Glucose induces β-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 2001;50:1683-1690
9. Maedler K, Størling J, Sturis J, et al. Glucose- and interleukin-1β-induced β-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 2004;53:1706-1713
10. Welsh N, Cnop M, Kharroubi I, et al. Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? Diabetes 2005;54:3238-3244
11. Maedler K, Sergeev P, Ehses JA, et al. Leptin modulates β cell expression of IL-1 receptor antagonist and release of IL-1β in human islets. Proc Natl Acad Sci U S A 2004;101:8138-8143
12. Interleukin-1 receptor antagonist and insulin sensitivity [Internet], 2010. Available from http://clinicaltrials.gov/ct2/show/NCT00928876. Accessed 12 April 2012
13. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-1526
14. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009;32:1663-1668
15. Donath MY, Weder C, Brunner A, et al. XOMA 052, a potential disease modifying anti-IL-1beta antibody, shows sustained HbA1c reductions 3 months after a single injection with no increases in safety parameters in subjects with type 2 diabetes [abstract online], 2009. Available from http://professional. diabetes.org/Abstracts-Display.aspx?TYP=1&CID=74494. Accessed 13 April 2012
16. Kineret (anakinra) prescribing information [Internet], c2001-2003. Thousand Oaks, CA, Amgen. Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2003/anakamg062703LB.pdf. Accessed 12 November 2012
17. American Diabetes Association. Standards of medical care in diabetesd2007. Diabetes Care 2007;30(Suppl. 1):S4-S41
18. Grundy SM, Cleeman JI, Merz CN, et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239
19. Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring) 2008;16: 1901-1907
20. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470
21. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005;48:1038-1050
22. Herder C, Baumert J, Thorand B, et al. Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002. Diabetologia 2006;49:921-929
23. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-867
24. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-1801
25. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008;118: 2992-3002
26. van Asseldonk EJ, Stienstra R, Koenen TB, Joosten LA, Netea MG, Tack CJ. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2011;96:2119-2126
27. Lee YH, Magkos F, Mantzoros CS, Kang ES. Effects of leptin and adiponectin on pancreatic β-cell function. Metabolism 2011;60:1664-1672
28. Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010;17:332-341
29. Carstensen M, Herder C, Kivimäki M, et al. Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 2010;59:1222-1227
30. Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJ. Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab 2007;9: 218-232